[Form 4] Boston Scientific Corp. Insider Trading Activity

Rhea-AI Filing Summary

FormFactor Inc. (FORM) – Form 4 filed 1 Aug 2025

CFO & SVP Global Finance Shai Shahar reported automatic equity-award settlements:

• 17,477 performance-based RSUs converted to common stock (Code M) at $0.
• 5,049 time-based RSUs converted to common stock (Code M) at $0.
• Tax withholding satisfied via surrender of 9,709 and 2,805 shares, respectively, back to the issuer at $28.93 (Code F).

Net result: executive added roughly 10,012 shares, lifting direct ownership to 54,159 shares. All derivative units tied to these awards are now fully settled; no open-market activity occurred. The transactions are routine compensation events and do not signal a strategic shift or valuation commentary.

Positive

• CFO’s direct shareholding increases by ~10k shares, modestly enhancing alignment with shareholder interests

Negative

• None.

Insights

Securities Analyst

TL;DR: Routine award settlement; CFO’s stake rises, no open-market selling—neutral impact.

The filing reflects vesting of previously granted RSUs/PRSUs. Because the shares withheld merely cover taxes, the CFO retains additional equity exposure, which can modestly align incentives. However, the absolute share count (~54k, ≈0.07 % of outstanding) is too small to influence control or signal a definitive view on valuation. No cash proceeds were received and no purchase on the open market occurred, so the economic impact on the company and float is negligible. I classify the market significance as not impactful.

Corporate Governance Expert

TL;DR: Standard equity-comp vesting; governance-neutral.

The Compensation Committee confirmed performance targets for the 2022-2025 PRSU grant, triggering full vesting. Settlement mechanics (Code F tax withholding) are typical and consistent with FormFactor’s equity plan. No red flags arise regarding insider timing, Rule 10b5-1, or unusual derivative retention. Share retention suggests commitment, yet the event doesn’t materially alter insider ownership patterns. Impact on governance risk profile: neutral.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Monson Jonathan

(Last) (First) (Middle)

300 BOSTON SCIENTIFIC WAY

(Street)

MARLBOROUGH MA 01752-1234

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
BOSTON SCIENTIFIC CORP [ BSX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	EVP and CFO

3. Date of Earliest Transaction (Month/Day/Year)
08/02/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	08/02/2025		M		1,090	A	$0.0000(1)	35,817	D
Common Stock	08/02/2025		F		528	D	$105.41	35,289	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Stock Units	(1)	08/02/2025		M			1,090	(2)	08/02/2025(2)	Common Stock	1,090	$0.0000	0.0000	D

Explanation of Responses:

1. Each restricted stock unit represents the Company's commitment to issue one share of Boston Scientific common stock.

2. Shares of common stock will be issued to the reporting person in four equal annual installments beginning on August 2, 2022, the first anniversary of the date of grant.

	/s/ Susan Thompson, Attorney-in-Fact	08/04/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

How many FormFactor (FORM) shares does CFO Shai Shahar now own?

After the reported transactions, the executive directly holds 54,159 common shares.

What price was used for tax withholding on the vested shares?

Shares were surrendered back to the issuer at $28.93 per share to cover taxes.

Were any open-market sales executed in this Form 4?

No. All dispositions (Code F) were automatic share withholdings for taxes; no open-market trades occurred.

What equity awards vested on 1 Aug 2025?

The filing shows vesting of 17,477 performance-based RSUs and the final tranche of 5,049 time-based RSUs granted on 1 Aug 2022.

Does the CFO have remaining unvested derivative securities from these grants?

No. Both award types reported here are fully settled, leaving zero derivative units related to them.